Bergenin exerts anti-cancer activity in hepatocellular carcinoma via the PI3K/Akt/mTOR and MAPK/ERK pathways

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

doi:10.1007/s10735-025-10498-0

Bergenin exerts anti-cancer activity in hepatocellular carcinoma via the PI3K/Akt/mTOR and MAPK/ERK pathways

· 2025

2Citations

Links

DOI

Journal

Unknown Journal

TL;DR

It is demonstrated that bergenin exerts anti-HCC effects by simultaneously targeting proliferation, apoptosis, and metastasis through dual inhibition of oncogenic PI3K/Akt/mTOR and MAPK/ERK pathways.

AI-generated by Semantic Scholar